UK markets closed

Coloplast A/S (CLPBY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
14.46+0.02 (+0.14%)
As of 12:17PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close14.44
Open14.29
Bid0.00 x 0
Ask0.00 x 0
Day's range14.24 - 14.56
52-week range13.64 - 18.90
Volume59,717
Avg. volume66,766
Market cap30.771B
Beta (5Y monthly)0.07
PE ratio (TTM)42.00
EPS (TTM)0.34
Earnings dateN/A
Forward dividend & yield0.29 (2.04%)
Ex-dividend date03 Dec 2021
1y target estN/A
  • Globe Newswire

    Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons

    Please see enclosed pdf. Attachment 26012022_trading_in_shares_MW

  • Globe Newswire

    Coloplast A/S - Allocation of Share Options

    Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below transactions concern allocation of share options. For further details, reference is made to Coloplast’s Remuneration Policy which was adopted in 2021. The policy is available on the group website at this

  • Globe Newswire

    Coloplast delivers solid start to the year with 6% organic growth in Q1 and a 32% EBIT margin before special items

    The company is updating its financial guidance for 2021/22 to reflect the Atos Medical acquisition, which is targeted to close on January 31, 2022. Organic revenue growth guidance is unchanged, expected around 7% at constant exchange rates. Reported growth in DKK is expected to be around 15% from previously around 8% due to positive currency movements and including 8 months of Atos Medical revenue. The reported EBIT margin before special items is expected to be around 31% from previously around